Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) CAO Michael R. Megna Sells 9,051 Shares

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) CAO Michael R. Megna sold 9,051 shares of the company’s stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $22.45, for a total transaction of $203,194.95. Following the completion of the transaction, the chief accounting officer now owns 26,528 shares in the company, valued at approximately $595,553.60. This trade represents a 25.44 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Kiniksa Pharmaceuticals Stock Up 2.0 %

Shares of NASDAQ:KNSA opened at $22.61 on Monday. The company’s 50 day moving average price is $19.99 and its two-hundred day moving average price is $22.13. Kiniksa Pharmaceuticals, Ltd. has a 12-month low of $16.56 and a 12-month high of $28.15. The firm has a market cap of $1.64 billion, a PE ratio of -161.49 and a beta of 0.48.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last issued its quarterly earnings results on Tuesday, February 25th. The company reported ($0.12) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.06). Kiniksa Pharmaceuticals had a negative return on equity of 7.31% and a negative net margin of 2.36%. The firm had revenue of $122.50 million for the quarter, compared to the consensus estimate of $123.42 million. During the same period last year, the company posted $0.35 EPS. The business’s revenue was up 46.9% on a year-over-year basis. On average, research analysts expect that Kiniksa Pharmaceuticals, Ltd. will post -0.55 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the stock. Wedbush restated an “outperform” rating and set a $34.00 target price on shares of Kiniksa Pharmaceuticals in a research report on Tuesday, February 25th. Citigroup assumed coverage on shares of Kiniksa Pharmaceuticals in a research report on Thursday. They set a “buy” rating and a $40.00 target price on the stock. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $37.17.

Institutional Trading of Kiniksa Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the company. Quarry LP bought a new stake in shares of Kiniksa Pharmaceuticals during the 3rd quarter worth approximately $50,000. Lazard Asset Management LLC bought a new stake in shares of Kiniksa Pharmaceuticals during the 4th quarter worth approximately $61,000. KLP Kapitalforvaltning AS bought a new position in Kiniksa Pharmaceuticals in the 4th quarter valued at approximately $158,000. Bellevue Group AG bought a new position in Kiniksa Pharmaceuticals in the 4th quarter valued at approximately $160,000. Finally, Tower Research Capital LLC TRC lifted its stake in Kiniksa Pharmaceuticals by 117.1% in the 4th quarter. Tower Research Capital LLC TRC now owns 8,483 shares of the company’s stock valued at $168,000 after purchasing an additional 4,575 shares during the last quarter. Institutional investors own 53.95% of the company’s stock.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.